Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 01, 2015
- Source ID
- 10.1016/j.bbmt.2014.12.010
Entities
People
- Alison W. Loren
- Baldeep Wirk
- Belinda R. Avalos
- Betty K. Hamilton
- Bipin N Savani
- Brian J. Bolwell
- Celalettin Ustun
- Christopher N. Bredeson
- Daniel J Weisdorf
- David I. Marks
- Edmund K Waller
- Edward A. Copelan
- Edwin P. Alyea
- Gregory A. Hale
- H. Jean Khoury
- Harry C. Schouten
- Jean-yves Cahn
- Jeffrey Szer
- Jorge Cortés
- Koen W. Van Besien
- Kwang Woo Ahn
- Luciano J. Costa
- Mahmoud Aljurf
- Mark R Litzow
- Mary M. Horowitz
- Matt E. Kalaycio
- Mehdi Hamadani
- Michael R. Grunwald
- Mukta Arora
- Muthalagu Ramanathan
- Nilanjan Ghosh
- Omotayo Fasan
- Rammurti T. Kamble
- Richard T. Maziarz
- Robert Peter Gale
- Wael Saber
- Xiaochun Zhu
- Yoshihiro Inamoto
Organizations
- ARIAD Pharmaceuticals
- Amgen
- Blue Cross Blue Shield Association
- Celgene
- CellGenix (Germany)
- Children’s Leukemia Research Association
- Elevance Health, Inc.
- GSK
- Kiadis Pharma (Netherlands)
- Leukemia & Lymphoma Society
- Medical College of Wisconsin
- Miltenyi Biotec
- National Cancer Institute
- National Heart, Lung, and Blood Institute
- National Institute of Allergy and Infectious Diseases
- National Marrow Donor Program
- Office of Naval Research
- Otsuka (United States)
- Roche (United States)
- Seagen
- Sigma-Tau Pharmaceuticals (United States)
- Swedish Orphan Biovitrum
- Terumo BCT (United States)